All In Biotech

Drug Trial Radar · NCT03780179

MMR at 6 Months Trial

Measles-mumps-rubella Vaccine at 6 Months of Age, Immunology, and Childhood Morbidity in a High-income Setting

Last checked: Nov 20, 2026Latest source record: Jan 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 6,540 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,540

Actual

Start

Apr 15, 2019

Primary completion

Jan 7, 2022

Study completion Jan 7, 2022

Sponsor

Lead sponsor
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 5 months, up to 7 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Randomised, double-blind clinical trial to test humoral and cellular immunogenicity, and potential in-direct beneficial effect of the MMRvaxpro-vaccine administered at 6 months of age

Conditions

  • Meales-mumps-rubella Vaccine

Interventions

  • MMRvaxproBiological

    MMRvaxpro vaccine

  • PlaceboBiological

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Humoral immunogenicityTime frame: 1 months after intervention
  2. Hospitalisation for infectionTime frame: 6-12 months of age

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Herlev Hospital

    Herlev, Denmark

  • Rigshospitalet

    Copenhagen, Copenhagen Ø, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.